je.st
news
Tag: approves fda
FDA Approves Marketing Of Bayers ProstaMate And OvaCyst Reproduction Management Products
2013-08-02 19:15:08| Beef
Bayer HealthCare LLC Animal Health Division received approval from the Food and Drug Administration (FDA) to market ProstaMate™ (dinoprost tromethamine) and OvaCyst™ (gonadorelin diacetate tetrahydrate) for indications in support of reproduction management as prescribed by veterinarians. ProstaMate is indicated for use in cattle, swine and mares; OvaCyst for use in dairy cattle. read more
Tags: products
management
marketing
reproduction
'Relight my (Cola) Fire?' FDA approves PureCircle Reb D stevia
2013-07-09 20:26:03| Beverages - Topix.net
No it's not Star Wars but Cola Wars, and could Reb D stevia breathe new life into the US conflict? The US FDA has issued a 'No Objection' GRAS letter allowing beverage manufacturers to use Pure Circle's high-purity Reb D stevia to sweeten US products, a move that could reignite the Pepsi/Coke cola wars.
U.S. FDA approves Orexo drug to treat opioid addiction
2013-07-04 21:12:00| Appliances - Topix.net
The U.S. Food and Drug Administration has approved Swedish drugmaker Orexo AB's drug to treat opioid addiction, the company said on Thursday, sending its shares up as much as 14.3 percent in Stockholm.
Tags: drug
treat
addiction
fda
FDA Approves New U.S. Labeling for ISENTRESS (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients
2013-07-01 23:05:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS (raltegravir) Film-coated Tablets, Mercks integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
include
study
adult
FDA Approves U.S. Product Labeling Update For Sprycel (Dasatinib) To Include Three-Year First-Line And Five-Year Second-Line Efficacy And Safety Data In Chronic Myeloid Leukemia In Chronic Phase
2013-06-20 16:10:00| dairynetwork News Articles
Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel (dasatinib) product labeling. The labeling now includes three-year efficacy and safety data in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and five-year data in CP Ph+ CML patients who are resistant or intolerant to Gleevec®1 (imatinib mesylate)
Sites : [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »